

**Letter to the editor:**

**VARIANT *BCR-ABL1* FUSION GENES IN ADULT PHILADELPHIA  
CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC  
LEUKEMIA**

Stephen E. Langabeer<sup>1\*</sup>

<sup>1</sup> Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland

\* Corresponding author: Stephen E. Langabeer: E-mail: [slangabeer@stjames.ie](mailto:slangabeer@stjames.ie),  
Phone: +353-1-4103576, Fax: +353-1-4103513

<http://dx.doi.org/10.17179/excli2017-793>


This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(<http://creativecommons.org/licenses/by/4.0/>).

Dear Editor,

Acute lymphoblastic leukemia (ALL) is the manifestation of malignant transformation and subsequent proliferation of either B- or T-lymphoid progenitor cells than manifests predominantly in the bone marrow. ALL is more frequent in children in whom long term survival has vastly improved in recent years, however, in adults this malignancy remains clinically challenging (Terwilliger and Abdul-Hay, 2017). The recent World Health Organization classification of acute leukemias considers subdivision of ALL types on the basis of cytogenetic and molecular abnormalities among which is B-cell lymphoblastic leukemia/lymphoma with the t(9;22)(q34;q11.2)/Philadelphia chromosome and *BCR-ABL1* rearrangement (Ph+ ALL) (Arber et al., 2016). Ph+ ALL is uncommon in childhood but increases in incidence with advancing age of presentation. The introduction of tyrosine kinase inhibitors into existing and new treatment regimens has improved the outlook for many adult Ph+ ALL patients resulting in the increased ability to proceed to hematopoietic allogeneic stem cell transplantation (Ronson et al., 2017). Most Ph+ ALL treatment algorithms now incorporate some measure of minimal residual disease (MRD) response into risk stratification which may be achieved through a number of laboratory approaches. These approaches need to be sensitive, fast, with a requirement for standardization (van Dongen et al., 2015).

Monitoring *BCR-ABL1* transcripts for MRD by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) is now an essential component in the management of Ph+ chronic myeloid leukemia and this approach may also be applied to Ph+ ALL patients as a means of assessing MRD and therefore therapeutic efficacy. While the vast majority of Ph+ ALL patients express either the common e1a2, or less frequent e13a2 or e14a2 *BCR-ABL1* fusion transcripts (Figure 1), a minority harbor variants, usually as a consequence of alternative splicing of either *BCR* or *ABL1* exons. Characterization of the exact *BCR-ABL1* fusion gene at diagnosis is therefore critical for design and selection of primers and probes for RT-qPCR analysis. Summarized within are the variant *BCR-ABL1* fusions that have been reported in Ph+ ALL to date (Table 1) and that result in the presence or absence of the encoded functional domains

of the oncogenic *BCR-ABL1* protein contributing to altered cellular adhesion, enhanced proliferation, inhibition of apoptosis and increased genomic instability of Ph<sup>+</sup> ALL (Figure 1).



**Figure 1:** Exonic structure of the variant *BCR-ABL1* transcript types reported in adult Ph<sup>+</sup> ALL. ins: inserted sequence

**Table 1:** Variant *BCR-ABL1* transcript types reported in adult Ph+ ALL

Transcript type	Reference
<b>E1a3</b>	Soekarman et al., 1990; Iwata et al., 1994; Wilson et al., 2000; Burmeister et al., 2007; Fujisawa et al., 2008; Langabeer et al., 2011; Chen et al., 2013; Shin et al., 2015; Sonu et al., 2015; López-Andrade et al., 2016
<b>E13a3</b>	Burmeister et al., 2007; Zhang et al., 2016
<b>E14a3</b>	Kurita et al., 2016
<b>E14a2 ins</b>	Hirota et al., 2000
<b>E6a2</b>	Burmeister et al., 2007
<b>E8a1 ins</b>	Deshpande et al., 2016
<b>E8a2 ins</b>	McCarron et al., 2011; Kim et al., 2012
<b>E19a2</b>	Jeon et al., 2011

Detection of the variant *BCR-ABL1* fusion genes should be considered when molecular and cytogenetic findings are discordant and can be achieved by a number of different RT-PCR strategies (Cross et al., 1994; van Dongen et al., 1999; Chasseriau et al., 2004; Burmeister and Reinhardt, 2008) with confirmation necessary by sequencing of atypical PCR products. As these variants are present in only a minority of Ph+ ALL cases, their influence on genotype and impact on outcome remain unknown.

### **Conflict of interest**

The author declares no conflict of interest.

### **REFERENCES**

- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2391-405.
- Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. *Leuk Res*. 2008;32:579-85.
- Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical mRNA transcripts in adult acute lymphoblastic leukemia. *Haematologica*. 2007; 92:1699-702.
- Chasseriau J, Rivet J, Bilan F, Chomel JC, Guilhot F, Bourmeyster N, et al. Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR. *J Mol Diagn*. 2004;6:343-7.
- Chen Y, Wang HW, Chen XH, Xu ZF, Qin YH, Ren FG, et al. Adult acute lymphoblastic leukemia with atypical BCR-ABL transcript e1a3: a case report and literature review. *Zhonghua Xue Ye Xue Za Zhi*. 2013; 34:965-6.
- Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. *Leukemia*. 1994;8:186-9.
- Deshpande PA, Srivastava VM, Mani S, Anandhan S, Meena J, Abraham A, et al. Atypical fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. *Leuk Lymphoma*. 2016; 57:2481-4.
- Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K. A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. *Int J Hematol*. 2008;87:184-8.
- Hirota M, Hidaka E, Ueno I, Ishikawa M, Asano N, Yamauchi K, et al. Novel BCR-ABL transcript containing an intronic sequence insert in a patient with Philadelphia-positive acute lymphoblastic leukaemia. *Br J Haematol*. 2000;110:867-70.
- Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. *Leukemia*. 1994;8:1696-702.
- Jeon EK, Lim J, Kim M, Yahng SA, Lee SE, Cho BS, et al. The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response. *Leukemia*. 2011;25:366-7.
- Kim MJ, Yoon HJ, Park TS. The e8a2 fusion transcript in B lymphoblastic leukemia with BCR-ABL1 rearrangement. *Korean J Haematol*. 2012;47:161.

Kurita D, Hatta Y, Hojo A, Kura Y, Sawada U, Kanda Y, et al. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript. *Cancer Genet.* 2016;209:161-5.

Langabeer SE, Haslam K, Kelly J, Leahy M, Vandenberghe E. Acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion. *Acta Haematol.* 2011;126:214-5.

López-Andrade B, Sartori F, Guitérrez A, García L, Cunill V, Durán MA et al. Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases. *Exp Hematol Oncol.* 2016;5:21.

McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, et al. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. *Leuk Lymphoma.* 2011;52:919-21.

Ronson A, Tvito A, Rowe JM. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia. *Curr Treat Options Oncol.* 2017;18:20.

Shin SY, Cho JH, Kim HJ, Jang JH, Lee ST, Kim SH. Two cases of acute lymphoblastic leukemia with an e1a3 BCR-ABL1 fusion transcript. *Ann Lab Med.* 2015;35:159-61.

Soekarman D, van Denderen J, Hoefsloot L, Moret M, Meeuwssen T, van Baal J, et al. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Leukemia.* 1990;4:397-403.

Sonu RJ, Jonas BA, Dwyre DM, Gregg JP, Rashidi HH. Optimal molecular methods in detecting p190 (BCR-ABL) fusion variants in hematologic malignancies: a case report and review of the literature. *Case Rep Hematol.* 2015;2015:458052.

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. *Blood Cancer J.* 2017;7:e577.

van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. *Leukemia.* 1999;13:1901-28.

van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. *Blood.* 2015;125:3996-4009.

Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR, et al. Are aberrant BCR-ABL transcripts more common than previously thought? *Br J Haematol.* 2000;111:1109-11.

Zhang X, Pan J. An e13a3 BCR-ABL1 fusion transcript in variant t(9;22;17)(q34;q11;q21)-positive adult acute lymphoblastic leukemia. *Int J Lab Hematol.* 2016;38:e52-5.